Biotechnology News and Research

RSS

Data generated on Ion Torrent PGM sequencer to be presented at AGBT

Life Technologies Corporation, today announced that just six weeks following the launch of the Ion Torrent PGM sequencer, independent researchers will present data they generated with the system at the annual Advances in Genome Biology and Technology (AGBT) conference.

4 Feb 2011

Tacere announces reacquisition of HCV compound development, commercialization rights in Asia

Tacere Therapeutics, an RNA interference (RNAi)-based therapeutics company, announced today that it has reacquired the development and commercialization rights to its Hepatitis C Virus compounds throughout Asia from its strategic partner, Tokyo-based Oncolys BioPharma Inc.

4 Feb 2011

AMRI's Burlington facility granted AIFA approval to manufacture octreotide

AMRI announced today that it has received approval from the Italian Medicines Agency (AIFA) for its facility in Burlington, MA to manufacture the commercial drug product octreotide for a customer in the European Union (EU).

4 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the investigational drug ILUVIEN for the treatment of Diabetic Macular Edema, today announced month 36, top-line readout results for the FAME Study prepared by its licensee, Alimera Sciences.

4 Feb 2011

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene, a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease.

3 Feb 2011

Nitto Denko announces acquisition of Avecia Biotechnology

Japan's leading diversified materials manufacturer, Nitto Denko Corporation, today announced that it has acquired Avecia Biotechnology, Inc. through Nitto Americas, Inc., a wholly owned subsidiary in Teaneck, New Jersey.

3 Feb 2011

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Genmab A/S announced today that the net sales for Arzerra® (ofatumumab) during the fourth quarter of 2010 were GBP 9 million (approximately DKK 77 million).

3 Feb 2011

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

In light of an aging population and increasing chronic vascular disease, there is a tremendous unmet need for new medical technologies to treat potentially dangerous chronic venous insufficiency (CVI) and blood clots, according to a Scientia Advisors review of the vascular device market released today. Both the CVI and the thrombosis segments present significant opportunities for medical device innovators.

3 Feb 2011

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert Pharmaceuticals, Inc. today announced that it has entered into a Cooperative Research and Development Agreement with the Walter Reed Army Institute of Research. The CRADA will allow the WRAIR to conduct preclinical testing on a novel compound derived from Concert's DCE Platform™ (deuterated chemical entity platform) for seizure protection associated with traumatic brain injury, a major public health concern.

3 Feb 2011

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune-based therapies for the treatment of various forms of cancer, announced today that the first patient has been enrolled in its Phase II trial of ICT-107 at the New Jersey Neuroscience Institute at JFK Medical Center. ICT-107 is the company's dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM).

3 Feb 2011

NIH awards CMU $1.2 million grant to analyze ethical, policy problems linked with DNA ID practices

Forensic DNA profiling has become a standard tool in the search for missing people in the aftermath of mass violence and disaster, but until now there has been very little effort to identify and analyze the major ethical and policy challenges associated with this new use of genetic technology.

3 Feb 2011

SAGE Labs, Cofactor Genomics partner to sequence genomes for six widely used rat strains

Sigma Life Science, the innovative biological products and services business of Sigma-Aldrich®, today announced that its SAGE Labs initiative has partnered with Cofactor Genomics in an effort to sequence genomes for six of the most widely used strains of rat.

3 Feb 2011

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively, researchers at Dana-Farber Cancer Institute report in a study published online today by the journal Nature. The discovery lays the groundwork for the first gene-based test for determining whether a man's prostate cancer is likely to remain dormant within the prostate gland, or spread lethally to other parts of the body.

3 Feb 2011

Study uncovers genetic hierarchy in plant sperm formation

Biologists at the University of Leicester have published results of a new study into the intricacies of sex in flowering plants.

3 Feb 2011

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

Seattle Genetics, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price to the public of $15.50 per share.

3 Feb 2011

Scientists challenged to sequence genome and RNA content derived from single cancer cell

Life Technologies Corporation today announced that the Life Grand Challenges Contest, initially introduced in December 2010, is expanding to include a fourth challenge. This latest contest challenges scientists to sequence the genome and all RNA content derived from a single cancer cell using the 5500 Series SOLiD™ Sequencers.

3 Feb 2011

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

EGEN, Inc. today announced that the Food and Drug Administration (FDA) has awarded the company a four-year grant of $1,600,000 to assist in the Phase II clinical development of EGEN-001, the company's lead product. EGEN-001 is under clinical development for the treatment of advanced recurrent ovarian cancer.

2 Feb 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios® Corporation today announced that it has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation, to develop phospholipid nanoencapsulated camptothecin, Camposomes™, for the treatment of pancreatic and other cancers, supporting the NCI Alliance for Nanotechnology.

2 Feb 2011

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has published today. In the February 1, 2011 issue of the journal CNS Drugs the first human results of a new method of targeting chronic brain inflammation years after stroke are reported.

2 Feb 2011

Biotechnology News and Research

Data generated on Ion Torrent PGM sequencer to be presented at AGBT

Tacere announces reacquisition of HCV compound development, commercialization rights in Asia

AMRI's Burlington facility granted AIFA approval to manufacture octreotide

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Positive top-line results from ILUVIEN Phase 3 trial in patients with DME

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Nitto Denko announces acquisition of Avecia Biotechnology

Genmab reports GBP 9 million net sales for Arzerra in fourth quarter 2010

Scientia Advisors: Unmet need for new medical technologies to treat CVI and blood clots

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

ImmunoCellular Therapeutics initiates enrollment in ICT-107 Phase II trial for GBM

NIH awards CMU $1.2 million grant to analyze ethical, policy problems linked with DNA ID practices

SAGE Labs, Cofactor Genomics partner to sequence genomes for six widely used rat strains

Four-gene/protein signature more accurately predicts metastatic prostate cancer

Study uncovers genetic hierarchy in plant sperm formation

Seattle Genetics prices underwritten public offering of 10,000,000 shares of common stock

Scientists challenged to sequence genome and RNA content derived from single cancer cell

EGEN receives 4-year, $1.6M FDA grant for EGEN-001 Phase II clinical study in ovarian cancer

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News